Eczema affects an estimated 20 per cent of children and 11 per cent of adults in Singapore. In its moderate to severe form, ...

Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The indication is for the treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate ...

People are also more likely to struggle with flare ups when air quality is considered 'moderate' - typically seen in the ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Study: High levels of pollution particles increase head & neck cancer How the air around us impacts our health. A new study ...

Dermatological drugs are a category of medications used to treat a wide range of skin conditions, including acne, eczema, psoriasis ... in patients with moderate to severe plaque psoriasis and scalp ...

Now, eczema isn’t something most people talk about much, but it affects between 2% to 10% of adults in the United States. For ...

The novel oral first-in-class anti-inflammatory agent has demonstrated robust efficacy and high safety margins in preclinical studies, and is the first drug candidate to advance to clinical trials ...